Bull
$14.87
情景价格
$9.440
-0.128 (-1.36%)收盘时
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.
BMO Capital
$12
2026-08-05
BMO Capital
2026-08-05
目标价
$12
UBS
$15
2026-07-28
UBS
2026-07-28
目标价
$15
Stephens
$15
2026-07-23
Stephens
2026-07-23
目标价
$15
Stifel
$13
2026-07-08
Stifel
2026-07-08
目标价
$13
Barclays
$24
2026-05-07
Barclays
2026-05-07
目标价
$24
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings Q2 2026 Earnings Highlights

Latest Wall Street Rating Changes

Alphatec Announces Upcoming Investor Conference Participation

Alphatec to Report Q2 2026 Financial Results on August 4
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.
3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。